Neos Therapeutics Inc  

(Public, NASDAQ:NEOS)   Watch this stock  
Find more results for Neos Therapeutics, Inc.�
8.60
-0.10 (-1.15%)
After Hours: 8.60 0.00 (0.00%)
Jul 26, 5:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.51 - 8.89
52 week 7.15 - 28.99
Open 8.71
Vol / Avg. 36,478.00/136,419.00
Mkt cap 135.66M
P/E     -
Div/yield     -
EPS -2.38
Shares 16.05M
Beta     -
Inst. own 56%
Sep 1, 2016
Q2 2016 Neos Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 21, 2016
Neos Therapeutics Inc at JMP Securities Life Sciences Conference
May 24, 2016
Neos Therapeutics Inc at UBS Global Healthcare Conference
May 16, 2016
Q1 2016 Neos Therapeutics Inc Earnings Release
May 16, 2016
Q1 2016 Neos Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -488.35% -811.74%
Operating margin -459.31% -700.90%
EBITD margin - -615.40%
Return on average assets -42.10% -36.70%
Return on average equity -69.87% -
Employees 81 -
CDP Score - -

Address

2940 N State Highway 360 Ste 400
GRAND PRAIRIE, TX 75050-6424
United States - Map
+1-972-4081360 (Phone)
+1-972-4081143 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Officers and directors

Alan Heller Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Vipin K. Garg Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Richard Eisenstadt Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Juergen A. Martens Ph.D. Chief Technology and Operations Officer
Age: 60
Bio & Compensation  - Reuters
Dorothy Engelking Vice President of Regulatory Affairs
Age: 54
Bio & Compensation  - Reuters
Thomas P McDonnell Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Beth P. Hecht Director
Bio & Compensation  - Reuters
Paul R. Edick Non-Executive Director
Age: 60
Bio & Compensation  - Reuters
Bryant E. Fong Non-Executive Director
Bio & Compensation  - Reuters
Gregory J. Robitaille Non-Executive Director
Bio & Compensation  - Reuters